These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

168 related items for PubMed ID: 10364175

  • 1. Real-time kinetics of HIV-1 Rev-Rev response element interactions. Definition of minimal binding sites on RNA and protein and stoichiometric analysis.
    Van Ryk DI, Venkatesan S.
    J Biol Chem; 1999 Jun 18; 274(25):17452-63. PubMed ID: 10364175
    [Abstract] [Full Text] [Related]

  • 2. Arginine side-chain dynamics in the HIV-1 rev-RRE complex.
    Wilkinson TA, Botuyan MV, Kaplan BE, Rossi JJ, Chen Y.
    J Mol Biol; 2000 Nov 03; 303(4):515-29. PubMed ID: 11054288
    [Abstract] [Full Text] [Related]

  • 3. The amino terminal domain of HIV-1 Rev is required for discrimination of the RRE from nonspecific RNA.
    Daly TJ, Doten RC, Rusche JR, Auer M.
    J Mol Biol; 1995 Oct 20; 253(2):243-58. PubMed ID: 7563086
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Exchange of the basic domain of human immunodeficiency virus type 1 Rev for a polyarginine stretch expands the RNA binding specificity, and a minimal arginine cluster is required for optimal RRE RNA binding affinity, nuclear accumulation, and trans-activation.
    Nam YS, Petrovic A, Jeong KS, Venkatesan S.
    J Virol; 2001 Mar 20; 75(6):2957-71. PubMed ID: 11222721
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Human immunodeficiency virus rev protein recognizes a target sequence in rev-responsive element RNA within the context of RNA secondary structure.
    Holland SM, Ahmad N, Maitra RK, Wingfield P, Venkatesan S.
    J Virol; 1990 Dec 20; 64(12):5966-75. PubMed ID: 2243382
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Specificity of aminoglycoside binding to RNA constructs derived from the 16S rRNA decoding region and the HIV-RRE activator region.
    Wang Y, Hamasaki K, Rando RR.
    Biochemistry; 1997 Jan 28; 36(4):768-79. PubMed ID: 9020774
    [Abstract] [Full Text] [Related]

  • 14. Evaluation of mismatch-binding ligands as inhibitors for Rev-RRE interaction.
    Nakatani K, Horie S, Goto Y, Kobori A, Hagihara S.
    Bioorg Med Chem; 2006 Aug 01; 14(15):5384-8. PubMed ID: 16603366
    [Abstract] [Full Text] [Related]

  • 15. Construction of HIV Rev peptides containing peptide nucleic acid that bind HIV RRE IIB RNA.
    Kumagai I, Takahashi T, Hamasaki K, Ueno A, Mihara H.
    Bioorg Med Chem Lett; 2000 Feb 21; 10(4):377-9. PubMed ID: 10714504
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Proflavine acts as a Rev inhibitor by targeting the high-affinity Rev binding site of the Rev responsive element of HIV-1.
    DeJong ES, Chang CE, Gilson MK, Marino JP.
    Biochemistry; 2003 Jul 08; 42(26):8035-46. PubMed ID: 12834355
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.